Skip to main content
Journal cover image

Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.

Publication ,  Journal Article
Khoury, T; Zirpoli, G; Cohen, SM; Geradts, J; Omilian, A; Davis, W; Bshara, W; Miller, R; Mathews, MM; Troester, M; Palmer, JR; Ambrosone, CB
Published in: Am J Clin Pathol
August 1, 2017

OBJECTIVES: Ki-67 has been proposed to be used as a surrogate marker to differentiate luminal breast carcinomas (BCs). The purpose of this study was to determine the utility of and best approaches for using tissue microarrays (TMAs) and Ki-67 staining to distinguish luminal subtypes in large epidemiology studies of luminal/human epidermal growth factor receptor 2 (HER2)-negative BC. METHODS: Full-section and TMA (three 0.6-mm cores and two 1.0-mm cores) slides of 109 cases were stained with Ki-67 antibody. We assessed two ways of collapsing TMA cores: a weighted approach and mitotically active approach. RESULTS: For cases with at least a single 0.6-mm TMA core (n = 107), 16% were misclassified using a mitotically active approach and 11% using a weighted approach. For cases with at least a single 1.0-mm TMA core (n = 101), 5% were misclassified using either approach. For the 0.6-mm core group, there were 33.3% discordant cases. The number of discordant cases increased from 18% in the group of two cores to 40% in the group of three cores (P = .039). CONCLUSIONS: Ki-67 tumor heterogeneity was common in luminal/HER2- BC. Using a weighted approach was better than using a mitotically active approach for core to case collapsing. At least a single 1.0-mm core or three 0.6-mm cores are required when designing a study using TMA.

Duke Scholars

Published In

Am J Clin Pathol

DOI

EISSN

1943-7722

Publication Date

August 1, 2017

Volume

148

Issue

2

Start / End Page

108 / 118

Location

England

Related Subject Headings

  • Tissue Array Analysis
  • Pathology
  • Middle Aged
  • Ki-67 Antigen
  • Immunohistochemistry
  • Humans
  • Female
  • Breast Neoplasms
  • Biomarkers, Tumor
  • Adult
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Khoury, T., Zirpoli, G., Cohen, S. M., Geradts, J., Omilian, A., Davis, W., … Ambrosone, C. B. (2017). Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods. Am J Clin Pathol, 148(2), 108–118. https://doi.org/10.1093/ajcp/aqx053
Khoury, Thaer, Gary Zirpoli, Stephanie M. Cohen, Joseph Geradts, Angela Omilian, Warren Davis, Wiam Bshara, et al. “Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.Am J Clin Pathol 148, no. 2 (August 1, 2017): 108–18. https://doi.org/10.1093/ajcp/aqx053.
Khoury T, Zirpoli G, Cohen SM, Geradts J, Omilian A, Davis W, et al. Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods. Am J Clin Pathol. 2017 Aug 1;148(2):108–18.
Khoury, Thaer, et al. “Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods.Am J Clin Pathol, vol. 148, no. 2, Aug. 2017, pp. 108–18. Pubmed, doi:10.1093/ajcp/aqx053.
Khoury T, Zirpoli G, Cohen SM, Geradts J, Omilian A, Davis W, Bshara W, Miller R, Mathews MM, Troester M, Palmer JR, Ambrosone CB. Ki-67 Expression in Breast Cancer Tissue Microarrays: Assessing Tumor Heterogeneity, Concordance With Full Section, and Scoring Methods. Am J Clin Pathol. 2017 Aug 1;148(2):108–118.
Journal cover image

Published In

Am J Clin Pathol

DOI

EISSN

1943-7722

Publication Date

August 1, 2017

Volume

148

Issue

2

Start / End Page

108 / 118

Location

England

Related Subject Headings

  • Tissue Array Analysis
  • Pathology
  • Middle Aged
  • Ki-67 Antigen
  • Immunohistochemistry
  • Humans
  • Female
  • Breast Neoplasms
  • Biomarkers, Tumor
  • Adult